Lupin, Lilly partner for improved access to diabetes treatment in India

01 Oct 2018 Evaluate

Lupin and Eli Lilly and Company (India) (Lilly India) have expanded their business partnership aimed at widening access to innovative diabetes medicines in India. Under the new partnership, Lupin will distribute and market Lilly’s Aplevant (dulaglutide), a once-weekly injection for type 2 diabetes treatment.

Aplevant (dulaglutide) is a once-weekly injectable solution for adults with type 2 diabetes mellitus. Lupin expects to make Aplevant available in India in October 2018.

This announcement builds on the Lupin and Lilly India business partnership initiated in 2011 to expand the promotion and distribution of Lilly’s diabetes portfolio in India where Lupin has a large network.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2176.25 -18.75 (-0.85%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×